

Value of Information

1. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. *Health Economics* 1996;5(6):513-24.
2. Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. *Medical Decision Making* 1998;18(1):95-109.
3. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. *Journal of Health Economics* 1999;18(3):341-64.
4. Claxton K. Bayesian approaches to the value of information: Implications for the regulation of new pharmaceutical. *Health Economics* 1999;8(3):269-74.
5. Claxton K, Neumann PJ, Araki S, et al. Bayesian value-of-information analysis - An application to a policy model of Alzheimer's disease. *International Journal of Technology Assessment in Health Care* 2001;17(1):38-55.
6. Meltzer D. Addressing uncertainty in medical cost-effectiveness analysis - Implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research. *Journal of Health Economics* 2001;20(1):109-29.
7. Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modeling. *Medical Decision Making* 2004;24(2):207-27.
8. Ades AE, Claxton K, Sculpher M. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. *Health Economics* 2006;15(4):373-81.
9. Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research - Some lessons from recent UK experience. *Pharmacoeconomics* 2006;24(11):1055-68.
10. Eckermann S, Willan AR. Expected value of information and decision making in HTA. *Health Economics* 2007;16(2):195-209.
11. Brennan A, Kharroubi SA. Efficient computation of partial expected value of sample information using Bayesian approximation. *Journal of Health Economics* 2007;26(1):122-48.
12. Basu A, Meltzer D. Value of information on preference heterogeneity and individualized care. *Medical Decision Making* 2007;27(2):112-27.
13. Barton GR, Briggs AH, Fenwick EAL. Optimal cost-effectiveness decisions: The role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfect information (EVPI). *Value in Health* 2008;11(5):886-97.
14. Coyle D, Oakley J. Estimating the expected value of partial perfect information: a review of methods. *European Journal of Health Economics* 2008;9(3):251-9.
15. Meltzer D, Basu A, Meltzer HY. Comparative effectiveness research for antipsychotic medications: How much research is enough? *Health Affairs* 2009; 28(5): w794-w808.
16. Basu A, Meltzer D. Quantitative methods for valuing comparative effectiveness information. *Biopharmaceutical Report_ Fall* 2010; 17(2): 2-10.
17. Meltzer DO, Hoomans T, Chung JW, et al. Minimal Modeling Approaches to Value of Information Analysis for Health Research. *Medical Decision Making* 2011;31(6):E1-E22.
18. Willan AR, Eckermann S. Optimal clinical trial design using value of information methods with imperfect implementation. *Health Economics* 2010;19(5):549-61.
19. Wilan AR, Eckermann S. Value of Information and Pricing New Healthcare Interventions. *Pharmacoeconomics* 2012;30(6):447-59.

Additional references

- Brennan A, Kharroubi SA. Expected value of sample information for Weibull survival data. *Health Economics* 2007;16(11):1205-25.
- Brennan A, Kharroubi S, O'Hagan A, et al. Calculating partial expected value of perfect information via Monte Carlo sampling algorithms. *Medical Decision Making* 2007;27(4):448-70.
- Claxton K, Ginnelly L, Sculpher M, et al. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. *Health Technology Assessment* 2004;8(31):1-+.
- Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). *Lancet* 2002;360(9334):711-5.
- Claxton K. Exploring uncertainty in cost-effectiveness analysis. *Pharmacoeconomics* 2008;26(9):781-98.
- Eckermann S, Karnon J, Willan AR. The Value of Value of Information Best Informing Research Design and Prioritization Using Current Methods. *Pharmacoeconomics* 2010;28(9):699-709.
- Eckermann S, Willan AR. Time and expected value of sample information wait for no patient. *Value in Health* 2008;11(3):522-6.
- McKenna C, Claxton K. Addressing Adoption and Research Design Decisions Simultaneously: The Role of Value of Sample Information Analysis. *Medical Decision Making* 2011;31(6):853-65.
- Tappenden P, Chilcott JB, Eggington S, et al. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis. *Health Technology Assessment* 2004;8(27):1-+.
- Tappenden P, Chilcott J, Ward S, et al. Methodological issues in the economic analysis of cancer treatments. *European Journal of Cancer* 2006;42(17):2867-75.
- Willan A, Kowgier M. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. *Clinical Trials* 2008;5(4):289-300.
- Willan AR. Analysis, sample size, and fewer for estimating incremental net health benefit from clinical trial data. *Controlled Clinical Trials* 2001;22(3):228-37.
- Willan AR. The value of information and optimal clinical trials design (vol 24, pg 1971, 2005). *Statistics in Medicine* 2006;25(4):720-.
- Willan AR, Lin DY. Incremental net benefit in randomized clinical trials. *Statistics in Medicine* 2001;20(11):1563-74.
- Willan AR. Optimal sample size determinations from an industry perspective based on the expected value of information. *Clinical Trials* 2008;5(6):587-94.